ICYMI: “Prescription drug prices climb into the stratosphere”

05-20-2015 Blog PostsPress Release

May 20, 2015 “Prescription drug prices climb into the stratosphere” by Trudy Lieberman, Rural Health News Service Note: Article originally printed in Sterling Journal-Advocate.  There’s no getting around it. Americans are using more medications and spending more for them. The latest evidence just came from Express Scripts, the pharmacy benefit manager, which acts as a middleman […]

Justifying After the Fact Is Not Justification

10-22-2014 Blog PostsPress Release

What the study should have asked is whether or not the price Gilead set for the therapy is appropriate for all patients–even asymptomatic patients–and whether or not such a large portion of potential societal value should accrue to one company.

[SF Business Times] Gilead’s $1,000-a-pill hepatitis C drug may make financial sense for prisons

10-20-2014 Media

Pricey new hepatitis C drugs, such as Gilead Sciences Inc.’s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers.

[The Morning Consult] The Gilead Effect

10-14-2014 Media

Perhaps no company has done as much as Gilead to propel the issue of high drug prices onto center stage or to lay bare the pharmaceutical industry’s approach to pricing new drugs.

[WSJ] Will ‘Son of Sovaldi’ Cause State Medicaid Programs to Erect High Hurdles?

10-13-2014 Media

How might state Medicaid programs cope with a new and equally expensive hepatitis C treatment from Gilead Sciences.

[MarketWatch] Sovaldi pricing raises debate over drug costs

10-1-2014 Media

With the California-based drug manufacturer Gilead Sciences planning to roll out another hepatitis C medication, academics said Wednesday that policy changes are needed in the costly drug market so the interests of patients, health insurers and pharmaceutical companies align.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.